the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most...
Annual Report 3rd Quarter Report 2nd Quarter Report 1st Quarter Report FY2021 - April 1, 2021 to March 31, 2022 145th Fiscal Year Annual Report 3rd Quarter Report 2nd Quarter Report 1st Quarter Report FY2020 - April 1, 2020 to March 31, 2021 144nd Fiscal Year Annual Report 3rd Quarter ...
References Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome. ClinicalTrials.gov. Published June 25, 2021. Last accessed June 14, 2024.https://classic.clinicaltrials.gov/ct2/show/NCT04940624. A Study of Soticlestat as an Add-on Therapy in Children, Teenage...
The agreement is expected to close by March 31, 2021, subject to the satisfaction of customary closing conditions, receipt of required regulatory clearances and, where applicable, satisfaction of local information and/or consultation requirements. Upon close, approximately 60 Takeda employees will have ...
人免疫球蛋白 (Takeda): 一种Immunoglobulin调节剂药物,由Baxter International, Inc. (Baxter International, Inc.)公司最早进行研发,目前全球最高研发状态为批准上市,作用机制: Immunoglobulin调节剂(免疫球蛋白调节剂),治疗领域: 肿瘤,免疫系统疾病,感染,在研适应症
the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with theU.S. Securities and Exchange Commissio...
520 Anniversary Report on the Annual Global Survey 2018. World Federation of Hemophilia. Available at:https://bit.ly/3hGDUzU. Last accessed January 2021. 6World Federation of Hemophilia. “Introduction to hemophilia: treatment.” Av...
Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 1, 2021 and in Codexis’ Quarterly Report on Form 10-Q filed with the SEC on May 7, 2021, including under the caption “Risk Fac...
Chart represents TKPHF Revenue and Revenue Estimate over Annual period The chart has 1 X axis displaying time periods. The chart has 1 Y axis displaying values. Data ranges from 0 to 30610861538.17536.. 08B16B24B32B40B Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025 (E)Mar...
Explore Takeda's 2024 Annual Integrated Report showcasing our dedication to global health and a brighter future. Discover our corporate philosophy, sustainable value creation, and innovative biopharmaceutical approaches.